CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy

Cystic fibrosis-related diabetes (CFRD) is a common complication of cystic fibrosis that is associated with worse outcomes and higher mortality rates. CF transmembrane conductance regulator gene (CFTR) modulators have shown favorable effects on lung function, pulmonary exacerbations, and nutrition s...

Descripción completa

Detalles Bibliográficos
Autores principales: Crow, Hanna, Bengtson, Charles, Shi, Xiaosong, Graves, Leland, Anabtawi, Abeer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547287/
https://www.ncbi.nlm.nih.gov/pubmed/36217440
http://dx.doi.org/10.1016/j.jcte.2022.100307
_version_ 1784805232180461568
author Crow, Hanna
Bengtson, Charles
Shi, Xiaosong
Graves, Leland
Anabtawi, Abeer
author_facet Crow, Hanna
Bengtson, Charles
Shi, Xiaosong
Graves, Leland
Anabtawi, Abeer
author_sort Crow, Hanna
collection PubMed
description Cystic fibrosis-related diabetes (CFRD) is a common complication of cystic fibrosis that is associated with worse outcomes and higher mortality rates. CF transmembrane conductance regulator gene (CFTR) modulators have shown favorable effects on lung function, pulmonary exacerbations, and nutrition status. However, data regarding effects of CFTR modulators on glycemic control among those with CFRD is lacking. In this retrospective study, CGM data was analyzed to determine effect of elexacaftortezacaftor- ivacaftor therapy (ETI), a CFTR modulator, on glucose control among patients with CFRD. No difference was seen in glucose patterns after 3- and 6- months of starting ETI.
format Online
Article
Text
id pubmed-9547287
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95472872022-10-09 CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy Crow, Hanna Bengtson, Charles Shi, Xiaosong Graves, Leland Anabtawi, Abeer J Clin Transl Endocrinol Original Research Cystic fibrosis-related diabetes (CFRD) is a common complication of cystic fibrosis that is associated with worse outcomes and higher mortality rates. CF transmembrane conductance regulator gene (CFTR) modulators have shown favorable effects on lung function, pulmonary exacerbations, and nutrition status. However, data regarding effects of CFTR modulators on glycemic control among those with CFRD is lacking. In this retrospective study, CGM data was analyzed to determine effect of elexacaftortezacaftor- ivacaftor therapy (ETI), a CFTR modulator, on glucose control among patients with CFRD. No difference was seen in glucose patterns after 3- and 6- months of starting ETI. Elsevier 2022-10-01 /pmc/articles/PMC9547287/ /pubmed/36217440 http://dx.doi.org/10.1016/j.jcte.2022.100307 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Research
Crow, Hanna
Bengtson, Charles
Shi, Xiaosong
Graves, Leland
Anabtawi, Abeer
CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy
title CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy
title_full CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy
title_fullStr CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy
title_full_unstemmed CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy
title_short CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy
title_sort cgm patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547287/
https://www.ncbi.nlm.nih.gov/pubmed/36217440
http://dx.doi.org/10.1016/j.jcte.2022.100307
work_keys_str_mv AT crowhanna cgmpatternsinadultswithcysticfibrosisrelateddiabetesbeforeandafterelexacaftortezacaftorivacaftortherapy
AT bengtsoncharles cgmpatternsinadultswithcysticfibrosisrelateddiabetesbeforeandafterelexacaftortezacaftorivacaftortherapy
AT shixiaosong cgmpatternsinadultswithcysticfibrosisrelateddiabetesbeforeandafterelexacaftortezacaftorivacaftortherapy
AT gravesleland cgmpatternsinadultswithcysticfibrosisrelateddiabetesbeforeandafterelexacaftortezacaftorivacaftortherapy
AT anabtawiabeer cgmpatternsinadultswithcysticfibrosisrelateddiabetesbeforeandafterelexacaftortezacaftorivacaftortherapy

Ejemplares similares